For individuals exposed to the virus, HIV-1–specific T-cell immunity may be important in predicting risk for — and protecting against — subsequent infection.
It is known that some HIV-1–exposed but uninfected individuals have HIV-1–specific immune responses, but what these responses mean remains unclear. Now, researchers have conducted a case-control study involving participants in the iPrEx trial (NEJM JW AIDS Clin Care Jan 2011and N Engl J Med 2010; 363:2587) to examine the relation between preinfection HIV-1 immune response and risk for subsequent infection.
Eighty-four preinfection peripheral blood mononuclear cell samples from participants who seroconverted were matched with 480 samples from those who remained seronegative. Although anti–HIV-1 responses were seen in both groups (63% and 72%, respectively; P=0.72), the nature of these responses differed. Higher-magnitude T-cell responses to v…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)